|
Granules India Limited (Granules.NS) Avaliação DCF
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Granules India Limited (GRANULES.NS) Bundle
Descubra o verdadeiro potencial da Granules India Limited (Granulesns) com nossa calculadora avançada de DCF! Ajuste as principais suposições, explore vários cenários e avalie como as mudanças afetam a avaliação dos Granules India Limited (Granulesns) - tudo dentro de um modelo abrangente do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25,452.4 | 31,960.3 | 37,271.7 | 45,119.2 | 45,063.7 | 52,174.7 | 60,407.8 | 69,940.1 | 80,976.6 | 93,754.6 |
| Revenue Growth, % | 0 | 25.57 | 16.62 | 21.05 | -0.12301 | 15.78 | 15.78 | 15.78 | 15.78 | 15.78 |
| EBITDA | 5,896.1 | 8,821.1 | 7,398.4 | 9,276.0 | 8,263.2 | 11,427.4 | 13,230.6 | 15,318.4 | 17,735.7 | 20,534.3 |
| EBITDA, % | 23.17 | 27.6 | 19.85 | 20.56 | 18.34 | 21.9 | 21.9 | 21.9 | 21.9 | 21.9 |
| Depreciation | 1,369.5 | 1,514.6 | 1,586.3 | 1,844.9 | 2,073.3 | 2,406.9 | 2,786.7 | 3,226.5 | 3,735.6 | 4,325.1 |
| Depreciation, % | 5.38 | 4.74 | 4.26 | 4.09 | 4.6 | 4.61 | 4.61 | 4.61 | 4.61 | 4.61 |
| EBIT | 4,526.6 | 7,306.5 | 5,812.1 | 7,431.1 | 6,189.9 | 9,020.5 | 10,443.9 | 12,092.0 | 14,000.1 | 16,209.3 |
| EBIT, % | 17.78 | 22.86 | 15.59 | 16.47 | 13.74 | 17.29 | 17.29 | 17.29 | 17.29 | 17.29 |
| Total Cash | 2,378.7 | 2,632.6 | 3,961.5 | 3,159.6 | 3,811.0 | 4,557.0 | 5,276.1 | 6,108.7 | 7,072.7 | 8,188.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7,008.4 | 8,118.2 | 9,542.0 | 9,621.5 | .0 | 10,420.5 | 12,064.9 | 13,968.7 | 16,172.9 | 18,725.0 |
| Account Receivables, % | 27.54 | 25.4 | 25.6 | 21.32 | 0 | 19.97 | 19.97 | 19.97 | 19.97 | 19.97 |
| Inventories | 4,384.3 | 7,821.8 | 9,785.5 | 11,494.1 | 13,005.5 | 12,760.7 | 14,774.4 | 17,105.7 | 19,805.0 | 22,930.2 |
| Inventories, % | 17.23 | 24.47 | 26.25 | 25.47 | 28.86 | 24.46 | 24.46 | 24.46 | 24.46 | 24.46 |
| Accounts Payable | 3,568.8 | 5,410.5 | 6,386.1 | 7,821.3 | 7,495.3 | 8,562.0 | 9,913.1 | 11,477.3 | 13,288.5 | 15,385.4 |
| Accounts Payable, % | 14.02 | 16.93 | 17.13 | 17.33 | 16.63 | 16.41 | 16.41 | 16.41 | 16.41 | 16.41 |
| Capital Expenditure | -1,844.8 | -2,713.4 | -3,977.1 | -2,117.9 | -3,805.8 | -4,126.8 | -4,778.0 | -5,532.0 | -6,404.9 | -7,415.6 |
| Capital Expenditure, % | -7.25 | -8.49 | -10.67 | -4.69 | -8.45 | -7.91 | -7.91 | -7.91 | -7.91 | -7.91 |
| Tax Rate, % | 25.93 | 25.93 | 25.93 | 25.93 | 25.93 | 25.93 | 25.93 | 25.93 | 25.93 | 25.93 |
| EBITAT | 3,365.4 | 5,699.6 | 4,299.3 | 5,586.5 | 4,584.6 | 6,775.6 | 7,844.8 | 9,082.7 | 10,516.0 | 12,175.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4,933.8 | 1,795.2 | -503.4 | 4,960.5 | 10,636.3 | -4,053.3 | 3,546.7 | 4,106.3 | 4,754.3 | 5,504.5 |
| WACC, % | 5.74 | 5.76 | 5.73 | 5.74 | 5.73 | 5.74 | 5.74 | 5.74 | 5.74 | 5.74 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 10,778.4 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 5,670 | |||||||||
| Terminal Value | 206,798 | |||||||||
| Present Terminal Value | 156,428 | |||||||||
| Enterprise Value | 167,207 | |||||||||
| Net Debt | 9,340 | |||||||||
| Equity Value | 157,867 | |||||||||
| Diluted Shares Outstanding, MM | 242 | |||||||||
| Equity Value Per Share | 651.40 |
What You Will Receive
- Customizable Excel Template: An adaptable Excel-based DCF Calculator featuring pre-loaded financial data for Granules India Limited (GRANULESNS).
- Actual Financial Data: Access to historical figures and projected estimates (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA %, and WACC.
- Real-Time Calculations: Instantly assess how your inputs affect Granules India Limited’s (GRANULESNS) valuation.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- Intuitive Layout: Organized for clarity and simplicity, complete with step-by-step guidance.
Key Features
- Comprehensive GRANULESNS Data: Pre-loaded with Granules India Limited’s historical financial performance and forward-looking assessments.
- Fully Customizable Parameters: Modify revenue growth rates, profit margins, WACC, tax rates, and capital expenditures as needed.
- Dynamic Valuation Framework: Automatically recalculates Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Analysis: Develop multiple forecasting scenarios to explore various valuation outcomes.
- User-Centric Interface: Intuitive, organized, and crafted for both professionals and novices.
How It Works
- Download the Template: Gain immediate access to the Excel-based GRANULESNS DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates the intrinsic value of Granules India Limited.
- Test Scenarios: Explore various assumptions to assess potential changes in valuation.
- Analyze and Decide: Utilize the findings to inform your investment or financial strategy.
Why Choose This Calculator for Granules India Limited (GRANULESNS)?
- Accurate Data: Utilize real financial metrics from Granules India Limited for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your specific forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants focusing on Granules India Limited.
- User-Friendly: An intuitive interface along with step-by-step guidance ensures accessibility for all users.
Who Can Benefit from This Product?
- Professional Investors: Develop comprehensive and trustworthy valuation models for portfolio evaluation.
- Corporate Finance Teams: Examine valuation scenarios to inform internal business strategies.
- Consultants and Advisors: Deliver precise valuation insights for Granules India Limited (GRANULESNS) to your clients.
- Students and Educators: Utilize real-world data to practice and instruct on financial modeling techniques.
- Pharmaceutical Enthusiasts: Gain insights into how companies like Granules India Limited (GRANULESNS) are valued within the market.
Contents of the Template
- Historical Data: Provides an overview of Granules India Limited’s (GRANULESNS) previous financial performance and baseline projections.
- DCF and Levered DCF Models: Comprehensive templates designed to assess the intrinsic value of Granules India Limited (GRANULESNS).
- WACC Sheet: Pre-configured calculations for Weighted Average Cost of Capital.
- Editable Inputs: Customize key assumptions such as growth rates, EBITDA percentages, and CAPEX forecasts.
- Quarterly and Annual Statements: An exhaustive overview of Granules India Limited’s (GRANULESNS) financial statements.
- Interactive Dashboard: Dynamically visualize valuation outcomes and future projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.